tiprankstipranks
Trending News
More News >
Intuitive Surgical (ISRG)
:ISRG
Advertisement

Intuitive Surgical (ISRG) AI Stock Analysis

Compare
8,106 Followers

Top Page

ISRG

Intuitive Surgical

(NASDAQ:ISRG)

Rating:78Outperform
Price Target:
$601.00
▲(26.98% Upside)
Intuitive Surgical's robust financial performance and positive earnings call are the primary drivers of its strong score. The company's strategic initiatives and strong operational metrics provide a solid foundation. However, high valuation and mixed technical indicators suggest some caution. Tariff impacts and international challenges also pose risks to future performance.
Positive Factors
Financial Performance
Q2 operating margins of 38.8% were the highest in 15 quarters and beat the street by 400bps, showing improved profitability.
Growth Drivers
Intuitive's growth profile is supported by factors like after-hours procedures, international adoption, new instruments like Force Feedback, and the broadening launch of DV5.
Negative Factors
External Challenges
Macro challenges in OUS markets continued to be a drag on system placements, indicating ongoing external pressures.
Market Competition
Risks include increasing competition, a slightly lower utilization growth rate in the U.S., uncertainty about ACA subsidy cuts, and remanufacturing noise.

Intuitive Surgical (ISRG) vs. SPDR S&P 500 ETF (SPY)

Intuitive Surgical Business Overview & Revenue Model

Company DescriptionIntuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
How the Company Makes MoneyIntuitive Surgical generates revenue primarily through the sale of its da Vinci Surgical Systems, as well as through recurring revenue streams from instruments and accessories and service agreements. The company sells its robotic systems to hospitals and surgical centers, which then purchase additional instruments and accessories for each procedure performed. These recurring sales contribute significantly to Intuitive Surgical's revenue. Additionally, the company offers service contracts to maintain and support the installed systems, providing another steady source of income. Key partnerships with healthcare providers and ongoing innovation in surgical technology further bolster Intuitive Surgical's earnings by expanding its market reach and enhancing its product offerings.

Intuitive Surgical Key Performance Indicators (KPIs)

Any
Any
Da Vinci Placements
Da Vinci Placements
Tracks the number of Da Vinci surgical systems placed, indicating market penetration and adoption of robotic-assisted surgery.
Chart InsightsDa Vinci placements have shown a strong upward trend, culminating in a significant surge at the end of 2024 and into 2025. The recent earnings call highlights robust procedure growth and successful launches, particularly of the Da Vinci 5 system in the U.S., which has contributed to this momentum. Despite challenges in international markets and supply constraints, the company remains optimistic with a revised growth forecast and continued innovation, such as FDA approvals for new procedures, indicating a strategic focus on expanding their advanced energy instrument portfolio.
Data provided by:Main Street Data

Intuitive Surgical Earnings Call Summary

Earnings Call Date:Jul 22, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 16, 2025
Earnings Call Sentiment Neutral
The earnings call presented strong financial and operational performance with notable growth in procedure volumes and successful product launches. However, macroeconomic challenges in international markets and tariff impacts were highlighted as concerns.
Q2-2025 Updates
Positive Updates
Record Revenue Growth
Revenue growth was reported at 21% year-over-year, reflecting strong procedure performance and capital placements.
Da Vinci Procedure Growth
Da Vinci procedure growth in the quarter was 17%, with benign general surgery leading U.S. procedure growth. International growth was driven by non-urology procedures.
Successful Launch of Da Vinci 5
The newest platform, Da Vinci 5, is in broad launch in the U.S. and received clearances in Europe and Japan. Customer feedback and adoption are positive.
Strong Performance in Emerging Markets
Regional performance highlights included strength in India, Korea, and distribution markets.
SP and Ion Systems Growth
SP procedure growth was strong at 88% year-over-year, and Ion procedures grew 52% to approximately 35,000 in the quarter.
Advanced Energy Instruments Progress
Received 510(k) clearance for vessel sealer curved, enhancing precision in narrow anatomical spaces.
Negative Updates
International Macro Challenges
Continued macro challenges in Japan, China, and Europe impacted capital placements.
Tariff Impacts on Gross Margin
Tariffs impacted gross margin by approximately 60 basis points, with an estimated full-year impact of 1% of revenue.
Potential Medicaid Coverage Changes
Uncertainty remains around potential impacts of fiscal policy changes to Medicaid recipients, which could affect the business.
Challenges in European and Japanese Markets
Ongoing financial and budgetary pressures in Japan, China, and Europe continue to impact capital performance.
Company Guidance
During the Intuitive Second Quarter 2025 earnings call, several key metrics and updates were highlighted. The company reported a 21% revenue growth, driven by a 17% increase in da Vinci procedures and strong capital placements, including 395 da Vinci systems. Of these, 180 were the newer da Vinci 5 systems, which have seen positive feedback and adoption. The installed base of da Vinci systems grew by 14% to almost 10,500 globally, with average system utilization rising by 2%. Specific regional growth included a 23% increase in procedures outside the U.S., with notable strength in India and Korea. The company's Ion systems also saw significant growth, with a 52% increase in procedures. Despite macroeconomic challenges in some international markets, Intuitive maintained strong financial performance, with a pro forma operating margin of 39% and a 23% increase in pro forma earnings per share. Looking forward, the company updated its 2025 procedure growth guidance to a range of 15.5% to 17% and expects a pro forma gross margin between 66% and 67% of revenue.

Intuitive Surgical Financial Statement Overview

Summary
Intuitive Surgical shows strong financial performance with stable profitability, robust growth, and excellent liquidity. The company effectively manages costs and generates substantial cash flow, with a strong balance sheet free of debt. High margins and efficient asset utilization further bolster its financial health.
Income Statement
85
Very Positive
Intuitive Surgical showcases strong financial performance with a consistent upward trajectory in revenue growth, marked at 4.34% from the previous annual report to TTM. The gross profit margin is robust at 67.09%, while the net profit margin stands at an impressive 28.42%. The company also maintains healthy EBIT and EBITDA margins of 28.20% and 34.42%, respectively, indicating effective cost management and operational efficiency.
Balance Sheet
90
Very Positive
The balance sheet is exceptionally strong with a debt-free status enhancing financial stability, evidenced by a zero debt-to-equity ratio. The equity ratio is high at 89.55%, reflecting strong capitalization. Return on Equity is a solid 14.39% in the TTM period, indicating effective utilization of shareholder funds to generate profits.
Cash Flow
88
Very Positive
Cash flow metrics are robust, with a significant free cash flow growth of 33.84% from the previous year. The operating cash flow to net income ratio is 1.10, and the free cash flow to net income ratio is 0.70, indicating strong cash generation relative to net earnings. These metrics suggest excellent liquidity and cash management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue8.71B8.35B7.12B6.22B5.71B4.36B
Gross Profit5.85B5.63B4.73B4.20B3.96B2.86B
EBITDA2.95B2.81B2.17B1.94B2.13B1.33B
Net Income2.48B2.32B1.80B1.32B1.70B1.06B
Balance Sheet
Total Assets19.22B18.84B15.44B12.97B13.55B11.17B
Cash, Cash Equivalents and Short-Term Investments4.51B4.01B5.22B4.12B4.23B5.17B
Total Debt0.00146.00M0.000.0087.00M0.00
Total Liabilities2.01B2.31B2.04B1.86B1.60B1.41B
Stockholders Equity17.11B16.43B13.31B11.04B11.95B9.76B
Cash Flow
Free Cash Flow1.75B1.30B749.60M958.40M1.74B1.14B
Operating Cash Flow2.73B2.42B1.81B1.49B2.09B1.48B
Investing Cash Flow-2.93B-3.27B-360.10M1.37B-2.46B-940.60M
Financing Cash Flow-38.20M150.90M-287.60M-2.57B43.00M-85.70M

Intuitive Surgical Technical Analysis

Technical Analysis Sentiment
Negative
Last Price473.30
Price Trends
50DMA
499.78
Negative
100DMA
513.13
Negative
200DMA
528.69
Negative
Market Momentum
MACD
-7.18
Negative
RSI
41.55
Neutral
STOCH
45.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISRG, the sentiment is Negative. The current price of 473.3 is below the 20-day moving average (MA) of 475.60, below the 50-day MA of 499.78, and below the 200-day MA of 528.69, indicating a bearish trend. The MACD of -7.18 indicates Negative momentum. The RSI at 41.55 is Neutral, neither overbought nor oversold. The STOCH value of 45.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISRG.

Intuitive Surgical Risk Analysis

Intuitive Surgical disclosed 47 risk factors in its most recent earnings report. Intuitive Surgical reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Intuitive Surgical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$40.19B28.8825.86%0.80%9.84%37.48%
78
Outperform
$169.67B66.0516.02%20.77%23.16%
75
Outperform
$55.31B34.706.26%2.11%7.86%14.24%
75
Outperform
$14.93B27.8511.38%1.28%-17.73%
65
Neutral
$13.40B33.185.01%6.35%12.94%
54
Neutral
$12.68B136.07-3.30%2.75%-27.41%67.01%
51
Neutral
$7.85B-0.21-41.41%2.22%22.81%-2.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ISRG
Intuitive Surgical
473.30
-10.14
-2.10%
BAX
Baxter International
24.69
-12.32
-33.29%
BDX
Becton Dickinson
192.98
-44.55
-18.76%
COO
Cooper Co
67.40
-38.66
-36.45%
HOLX
Hologic
67.12
-15.04
-18.31%
RMD
Resmed
274.51
31.72
13.06%

Intuitive Surgical Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Intuitive Surgical Appoints David Rosa as CEO
Positive
May 15, 2025

On May 14, 2025, Intuitive Surgical‘s Board of Directors appointed David J. Rosa as the new Chief Executive Officer, effective July 1, 2025. Rosa, who has been with the company for 29 years, will replace Gary S. Guthart, who will transition to Executive Chair of the Board. This leadership change is part of the company’s strategic succession planning to drive future growth. The announcement highlights Rosa’s extensive experience and contributions to Intuitive’s strategy and product development, positioning him as the right leader to continue advancing the company’s mission and expanding its global footprint.

The most recent analyst rating on (ISRG) stock is a Buy with a $525.00 price target. To see the full list of analyst forecasts on Intuitive Surgical stock, see the ISRG Stock Forecast page.

Shareholder MeetingsStock Buyback
Intuitive Surgical Expands Stock Repurchase Program to $4B
Positive
May 5, 2025

On May 1, 2025, Intuitive Surgical‘s stockholders approved several proposals at the annual meeting, including the amendment and restatement of the 2010 Incentive Award Plan, which increases the number of shares reserved for issuance and extends the plan’s term. Additionally, the company announced an increase in its stock repurchase program to $4.0 billion, indicating a strategic move to enhance shareholder value and manage its capital structure.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 09, 2025